(Q37799821)

23 August 2017

title

Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? (English)

1 reference

metastatic renal cell carcinoma

23 August 2017

1 reference

1 reference

2

Lisa Pickering

1 reference

23 August 2017

Robert Goldstein

1

1 reference

23 August 2017

James Larkin

series ordinal

3

1 reference

23 August 2017

publication date

1 October 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1545-1557

1 reference

Targeted therapies in metastatic renal cancer in 2009.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

The impact of O2 availability on human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Targeting VEGF receptors in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Early clinical studies of novel therapies for thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Tyrosine kinase inhibitors and the thyroid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.134

21 January 2018

Identifiers

DOI

10.1586/ERA.10.134

1 reference

23 August 2017

1 reference